Hematological Disorders Clinical Trials

People with hematological cancers are asked to participate in a research study being conducted by CLL Research and Treatment Program/Northwell Health Cancer Institute//Feinstein Institute for Medical Research and Zucker School of Medicine at Hofstra-Northwell  

The research procedures will be conducted at the University of Kentucky (UK) Medical Center. Participants in the study will provide ovarian tissue cryopreservation for their own personal use. The duration of the study will be until the participant reaches age 41 years. Participants will be broken out into four categories: ...

There has been a marked increase in our knowledge of Blood Disorders in the last decade. Much of this knowledge comes from examining blood specimens from patients and subjecting these samples to red cell, plasma, serum or DNA analyses. We propose to set up a Hematology biobank, which will include ...

Sometimes, certain patients, while the treatment comes to an end and while a remission is possible, present psychological and emotional difficulties. The return in a " new life " is lived as a factor of often unexpected stress which force the patients, from the end of the treatment, to reconsider ...

Therapeutic drug monitoring (TDM) offers the possibility to individualize and improve a patient's pharmacological treatment, based on the measurement of drug concentrations in biological samples. Conventionally, TDM is performed with blood or plasma obtained by venous blood sampling. This method is associated with several challenges such as i) the need ...

The investigators will detect platelet antibodies of participants who are according with the inclusive criteria. For participants with platelet antibodies, the investigators should screen out cases owning HPA antibodies and further to identify their genotype. Platelet infusion of same type will be applied to half of participants with HPA antibodies ...

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only treatment option with a significant chance of healing in lymphoid hematological refractory or multiple relapses after chemotherapy. However, all patients with an indication of allo-HSC can not benefit because of two limitations: the toxicity of the treatment and graft shortage available. ...

PRIMARY OBJECTIVES: I. To compare the overall survival (OS) rate at 2 years post treatment using the Jefferson 2 step reduced intensity conditioning (RIC) approach in patients with haploidentical family donors with hematological malignancies in morphological or radiographic remission or with chemosensitive, indolent diseases to historical OS rates in similar ...

Pain is the main reason why SCD patients are admitted and readmitted to the hospital. In fact, readmission rates of SCD patients are higher than those of asthmatics and diabetics. In order to reduce 30-day hospital readmission rates and improve patient care quality, the Affordable Care Act and Centers for ...

Given the growing number of patient contacts at our day-care center, there is a continuous search to further improve the flow and to shorten the time spent per patient at the day-care center, without loss of quality in care. In order to achieve this goal, this study wants to compare ...